AI predicts liver cancer return, guides precision treatment

NCT ID NCT07282184

Recruiting now Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Dec 16, 2025 · Last updated May 23, 2026 · Updated 22 times

Summary

This study is for people with early-stage liver cancer who are scheduled for surgery. Researchers are using an artificial intelligence tool to analyze each patient's scans and health data to predict their personal risk of the cancer returning. Patients identified as high-risk will receive medication before and after surgery, and their outcomes will be compared to those who have surgery alone. The goal is to see if this personalized approach can better prevent the cancer from coming back within two years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPOTACELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tongji Hospital
RECRUITING

Wuhan, Hubei, 438700, China

Contact Email: •••••@•••••

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEPOTACELLULAR CARCINOMA